Ps1063 results of pivotal phase 2 clinical trial of tagraxofusp (sl-401) in patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn)N. Pemmaraju,A. Lane,K. Sweet,A. Stein,S. Vasu,D. Rizzieri,E. Wang,M. Duvic,S. Spence,S. Shemesh,C. Brooks,I. Bergstein,J. Chen,P. McDonald,J.M. Sloan, T. Rosenblat,O. Akilov,J. Lancet,H. Kantarjian, M. KonoplevaHemaSphere（2019）引用 10|浏览0暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
